Table 2.

Incidence and patterns of treatment failure in patients among treatment approaches in early-stage FL

	RT alone, n = 171		Systemic therapy,* n = 60		Systemic therapy + maintenance rituximab, n = 49
	n/N	%	n/N	%	n/N	%	P
Total relapses	42/171	24.6	11/60	18.3	2/49	4.1	.006
In-field relapse only	3/171	1.7	3/60†	5.0	0/49	0	.254
In-field and distant relapse	4/171	2.3	2/60	3.3	0/49	0
Distant relapse only	35/171	20.4	6/60	10.0	2/49	4.1
Transformation	11/171	6.4	2/60	3.3	0/49	0	.145
Lymphoma-related mortality	6/171	3.5	2/60	3.3	2/49	4.1	.694
All-cause mortality	12 /171	7.0	3/60	5.0	2/49	4.1	.976

^*Systemic therapy includes immunochemotherapy and CMT.

^†Includes patients treated with systemic therapy only who relapsed at the site of initial disease.